Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present this latest issue of touchREVIEWS in Endocrinology, which brings together a diverse array of high-quality articles focused on the evolving landscape of endocrine disorders. The importance of patient-centred care is exemplified in the commentary by Bharti Kalra et al., which discusses the international guidelines for polycystic ovary […]

Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 1st 2023

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the next steps in the clinical development of CM-101.

The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.

Questions:

  1. What were the primary and secondary endpoints and how well were they achieved? (0:14)
  2. What will be the next steps in the clinical development of CM-101? (4:41)

Disclosures: Rifaat Safadi is a consultant for Chemomab.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.

Filmed in coverage of EASL 2023

Access further content on liver disorders

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup